Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Will Daniel Jorgensen return as CMO? He seems like the perfect fit with more advanced knowledge about B."
I doubt it. He, along with Edward Walters, appear to be doing ok in PA.
https://ocugen.com/about/executive-management/
https://www.linkedin.com/in/edward-j-walters-a55a0714
Too funny.
"Dr. Bertolino’s resignation was not a result of any disagreement with the Company."
Typical boiler plate lingo for many 8-k's regarding departing officers/directers.
I'm just curious as to why he left and realize, like so many things this company does(if they do any thing), we'll likely never know. I'll leave another message with the secretary, Anita, and wait for a return call.
"BUT I believe her introduction to the Company was through Dr B, so we'll see if she sticks around."
I think you're right. Hope we don't a New Year's Eve filing....
"....Dr. Barry Schechter and Dr. Zorik Spektor."
Tits on a bull. What have those two ever done?
"Dr. B out could be :
1 - Leo slashing payroll
2 - partner negotiating with wants him out
3 - Dr. Bert left for personal reasons"
Or:
4. Disagreement(s) with ceo as far as company operations/ethics.
"Ehrlich continued: “Given the industry buzz around the recent IPOs of Galera Therapeutics and Monopar Therapeutics, each with late-stage drug candidates targeting Oral Mucositis, we feel confident about the competitive positioning and commercial prospects of oral rinse Brilacidin as a preventative OM drug candidate and the considerable value it can bring to our company. The investment community seems to be waking up to the large unmet need in this area. We anticipate an active partnering process, with meetings scheduled with pharmaceutical companies interested in Brilacidin-OM during the 2020 J.P. Morgan Healthcare conference this January in San Francisco. A licensing deal for the Brilacidin-OM asset would bring significant upside for our shareholders.”
We- Who is "we"? How many employees are left in that ~1/4 acre office building? Is Jane Harness with ipix? What is the company's chain of command?
the 2020 J.P. Morgan Healthcare conference - Sounds as though it's back to square one.
What a surprise.
"Well I hope Leo made it to the coal mine today to pick up our xmas gifts! The lumps should be bigger than last years!"
Too much work for him.....he doesn't sweat or get dirty.
"Cashless Oncbimune, a company claiming to be starting two Pll trials at prestigious hospitals, "bought" a Mexican bio company with claimed products that it then closed down in less than a year, but not before a $600k debt transfer which no doubt go down with the ship. Then they hired a well known Oncologist who promised a few things right before a 750:1 rs. Then he quit. The trials were just a story as it turns out. Meanwhile the CFO/President-one-man-show with no particular skills has been making a handsome salary for decades."
Oncibiomune(obmp) has had 3 spilts. The first was 3:1forward split on 8/7/13,the second a 1:139.233 on 8/28/15, and the third a 1:750 on 9/12/19.
By my math, one would have to have 3,480,825 shares prior to 8/7/13 to have 100 shares of obmp today. It appears the sp of obmp was ~ 60 cents prior to the first split(if I did the math right. Ameritrade shows the closing price at $20,884.8841 on 8/6/19). OBMP closed today at today at$.1326. Todays 100 shares are worth $13.26. Those same shares would have cost ~$60 on 8/6/19. 13.26/60= .221 or a loss of 77.9%.
IPIX (CTIX) sp 8/6/13 was ~$1.95 on 8/6/13 vs $.0589 today. .0589/1.95= .0302 or a loss of 96.98%. IPIX has had no spilts if one purchased 100 shares on 8/6/19 at a cost of $195, they are worth $5.89 today.
Net loss comparison todays worth minus 8/6/19 cost):
ibmp: $13.26-60= -46.74
ipix: $5.89-$195= -$189.11
One would have suffered less loss, by comparison,investing in the other Nevada incorporated company.
100 shares $195 paid on 8/6/19
"IPIX did a good job in joining with elite organizations to develop their Brilacidin pill. In the long run will prove to be a godsend IMO. OM also now in a form to provide the easiest and least costly delivery system to the patient. Great drugs, great delivery systems, low cost, good times ahead."
Time will tell, but time is money and time does not stop. Money however, is running out as ipixstrings things out/trysnew endeavors of past, highly proclaimed accomplishments. If the first of the B applications for their targeted afflictions where so successful, as declared by the company, why switch delivery system(s)? This management team appears to be most efficient at wasted time.
I know, some ridicule some long investor's who wonder why the science, as previously presented as stellar, will be be changed and are upset with this investment, and question the change. The wonderers must be dopes!
"Looks like we now have 2 "Pro" posters on this board or maybe one bought the title from his other self. Weird." Agree 100%, you've done well.
"Interesting Thanks, Try this link. What is Gama Scintigraphy."
It's been around quite awhile (since 1966, see the 6th pragraph in the article #1 below) where it's stated "Gamma scintigraphy was first reported for the measurement of transit times in 1966 (gastric emptying) followed swiftly by the assessment of drug product performance in 1976 (capsule disintegration) (4,5).".
1. https://www.ddw-online.com/enabling-technologies/p149555-in-vivo-imaging-in-drug-development:-gamma-scintigraphy.html
2. Scintipharma, inc has apparently been in voved with 3 clinical trials(ecluding ipix) best I can tell.
https://clinicaltrials.gov/ct2/results?term=scintipharma%2C+inc&draw=2&rank=3#rowId2
"Looking at the trades the stock went down from .065/.07 to .0509/.052 while someone bought +/-200k. During that time there were only 35k sold. That had to be a market maker covering a short."
Squirmy is in control again?
Damn right. A nephew works for the SEC and has been made aware of this.
""Where are the IPIX sellers? Last transaction was 47 minutes ago."
A declared expert, and likely a few others, are likely planning their next raid. The "A" team(aka team collusion) "knows".
I don't think we're doing a R/S or a significant share sale agreement."
Why?
"I don't think we're doing a R/S or a significant share sale agreement."
Why? What else can they do to this Lubitz like control of sp trajectory to save shareholders?
"The hope is we will land a subsistence B-OM deal that will allow us to advance B-UC and Kevetrin through oral phase 2 trials. That will allow lucrative partnerships without decimating the current share structure."
Hope so.
"Funding B-OM Phase 3, B-UC Phase 1 and 2, and Kevetrin Phase 2 oral will likely balloon our share count toward 700M-900M. It will cost current shareholders tremendous equity percentages of ALL drugs in the pipeline BEFORE we partner them for 20% royalties."
Bill Gates and Steve Ballmer used their noggins, tey had brains. Leo has likely not lifted a garage door in his life, which is the office in which Microsoft started.
"It's clear we need either B-UC or Kevetrin to succeed in a phase 2 oral trial if we ever hope to get back to CTIX valuations. Holding out hope they can secure a B-OM deal that facilitates this."
Funny, all of the above imho.
I bought 200M NR shares today! I'm in like Flynn! Shorts, beware!
"I think Leo is following a plan that continues to leave those short no easy escape, they are trapped hence the anger displayed here."
Really? My shares are in an IRA(as I'm sure many other shareholders shares are as well). IRA shares can not be shorted.
If one were an expert at shorting, as you proclaim to be, I'd guess they would be quite successful on Wall St.
"Nonprofit Is on a Mission to Fund Research into a Cure for IBD"
Sounds like ipix.
"Every hour of every day the rage continues as B moves forward !"
Correct, the rager's(management) over the years are responsible to steer this company. And look where we sit....on a sand bar temporarily spared from going over the falls.
"More lies from Leo today. Now the trials won't begin until mid 2020!!!! what happened to December 2019. the guy is a god damn liar."
LE is the Hannibal Lector of ceo's.
Resign??? He will be arrested and tried.
The management is so weak they have not the arm strength to lift a ringing phone. I believe they have become exhausted themselves from having to continually repeat their unproven declarations.
"Beats the heck out of selling 15 million shares to raise the money."
True.
"We sure could use that $1 million."
Sure could, would extend their viability ~ an additional month.
"Today's headline was "Coverage Indicates 3X Greater Revenue Potential for Brilacidin Oral Rinse".
That seemed to refer to this, from the text:
"Most glaring was the analyst’s model projecting a course of treatment for Galera’s GC4419 at $15,400 (net). The price point is viewed as in-line with other supportive care treatments.
We conservatively modeled our Brilacidin Oral Rinse pricing at $5,000 for a course of treatment, leaving plenty of room for upward adjustment while providing the opportunity for a decisive pricing advantage."
I can point to the analysts support for that $15,400 cost number for Galera:
"We assume a course of therapy consists of 35 doses, administered over seven weeks, at a gross price of $550/dose, or $15,400 per course of therapy, net of applicable discounts and rebates (we assume 20%)."
So one IV infusion a day for 5 days a week at $550/infusion.
What I'm having trouble determining are the details of the Brilacidin Oral Rinse pricing for a full course at $5,000. Do you know where I can find them?
In the Phase 2 study:
"Patients will use an oral rinse 3 times daily for up to seven weeks during chemoradiation for head and neck cancer."
Is that the same rate of dosing that is reflected in the $5,000 course? 3/day for 7 5 day weeks is about $48/dose.
I couldn't find that anywhere, including here:
http://www.ipharminc.com/press-release/2019/11/13/innovation-pharmaceuticals-oral-cancer-on-the-rise-company-offers-perspectives-on-opportunity-of-brilacidin-for-the-prevention-of-oral-mucositis"
Yes, same dosage frequency: https://clinicaltrials.gov/ct2/show/study/NCT02324335?term=innovation+pharmaceuticals&draw=2&rank=2
"Does the "3X Greater Revenue Potential for Brilacidin Oral Rinse" come from an assumption that there is room for a tripling of the previously unknown price per dose of B-OM."
My thoughts, for your reflection. They(ipix) stated:
We conservatively modeled our Brilacidin Oral Rinse pricing at $5,000 for a course of treatment, leaving plenty of room for upward adjustment while providing the opportunity for a decisive pricing advantage."
I believe it likely boils down to pricing vs costs. If Galera costs are much higher, particularly due to administration costs((iv supervision(over paid healthcare ceo's/underlings), etc, money grubbers)/administration/documentation)), in today's age of fumble, stumble, and trip, it takes not long to escalate things, costs included.
"I need it dumbed down for me. Care to give it a try?"
My thoughts on the matters.
LR,
Excellent explanation. To quote Rodney Dangerfield from a movie(Back to School)- "Don't mind Lou- he's only the second generation in his family to stand up straight";)
"Does any bio have any proof that their drug will work or be accepted by the FDA prior to actually getting approval by the FDA? Of course not." I could not agree more.
"All they have to go on is pre-clinical and clinical trial results.
If those are good, expectations for partnering are justified." For the most part public companies are obligated to share their findings with shareholders', honestly. I believe man investor's have become somewhat skeptical based upon r.o.i compared to company proclamations.
"So for an investor to supposedly have thrown a ton of cash into a bio investment, suffer major losses due to buying at the wrong time or buying too early in the life cycle of the clinical trials, then IMO that makes them one hell of a poor investor if they then claim the risk was too great and is still too great far into the trial cycle." I guess some are better at reading the tea leaves than others-https://investorshub.advfn.com/boards/read_msg.aspx?message_id=80937422.
"Brilacidin OM keeps regularly checking off every box that must be stamped prior to approval and until it fails to do so my expectation is for it to succeed. Having done well thru a P2 means that many more times will the drug in trials succeed as opposed to failing as only a P3 is left to pass." Sounds failiar-https://investorshub.advfn.com/boards/read_msg.aspx?message_id=80937422
"Risk still at hand, yes. But risk that many BPs will accept in their quest to land a drug with multi-billion dollar per year potential." Not much risk left, only pennies to loose. Where have you gone Boston Business Journal?
"Like our chances." Never been better?!??
Intersting, TY, wasn't aware that Galera went public. Could not have been long ago as I've made it a point to periodically check their website for news.
Perhaps a fraudster,or both?
Another Bay Street piece(rag out of Canada)? Nothing from my brokerage firm,
"Well it's called business and AS held the carrot." Appears, to me, they've never had any internal cash flow(the cfo evidently loaned some $ at a nice rate of return, like one of his son's did as an executive at the ceo's former employer). Other than that its all been other people's money, given at discount rates, at shareholders' expense.
"Being out of cash Leo had little power at the negotiations table luckily for us we had very positive results in a small UC/UPS trial." Their pockets have always been empty and they have drained shareholders' pockets via questionable partners(Aspire, unnamed mfo, and some before). How long ago were those UC/UPS trial results? I realize Rome wasn't built in a day, but this management team appears worthy of a special needs evaluation based upon comparing public response to company declaration's. One flew over the cuckoo's nest?
"I hope AS makes a billion dollars it will make our 6% look pretty good." Don't we all, nothing left to loose.
"Next IBD deal should be huge for us." Perhaps, time tell. Let's hope it's bigger than P(prurisol), pumped early and often by a now seldom poster(the $15 billion dollar man), not to mention another poster(Nerby- where have yee gone?) who shared a bogus first hand account from a supposed trial patients relative.
Our ceo makes Rip Van Winkle look like a world class triathlete.
Good vibrations from this company for years has resulted in nothing but a crumbled share price and shareholder destruction....
"Get'r done Leo & Dr. B!" Appears he's done this company in.
I agree. Facts are important. I only wish I was good at math and english and able to decipher the importance of the information so religiously provided.
I must say I do appreciate humor, and chuckled when I read:
"54% of today's volume was short sales
54%! That's almost half!!!"
Had a physics professor (WWII vet) who often stated that "almost only counts in horseshoes, hand grenades, and atom bombs".
"I know, in some circles calling for over $2 over ten months from now constitutes bashing. Will it help if I said the stock will have hit over $3.50 before correcting back to over $2?"
The only way I see that happening is a 1:50 reverse split which, if it happened today at 7 cents, would put ipix at 3.50/sh. From there I agree, it would likely continue downward to $2.00/sh (down ~43% from 3.50). More of the same.
"Can you imagine if they can perfect Kevetrin to not only treat cancer but also all sorts of brain maladies????"
The dynamic duo can't manage a lease, so in response to your question I can't they can perfect Kevetrin to not only treat cancer but also all sorts of brain maladies.
"Company remains engaged with suitors..."
All according to the ceo. What past statements of his have been backed up with success and increased shareholder value?
Begging the Colonel's pardon, but wasn't Hogan Lovells hired for the same task? Are not they considered experts in M&A, and the likes?
WTF is all I can say. No other words, or expressions, are worthy.
He's proven himself full of it, and more than worthy of further investigation.
TY,
If only the ceo were to share as much info with shareholders.
How were you able to discern what you shared with us?
In response to:
"This is why we did not uplist, nor will we be doing a reverse split in the near term, unfortunately......"